Research publications

CHRU’s scientific output and contribution

Publications

CHRU Publications

Featured

Publication Date:

December 2023

Building sustainable clinical trial sites in Sub-Saharan Africa through networking, infrastructure improvement, training and conducting clinical studies: The PanACEA approach

Featured

Publication Date:

September 2023

The lived experiences of Tuberculosis survivors during the COVID-19 pandemic and government lockdown in South Africa: a qualitative analysis

Featured

Publication Date:

August 2023

Contemporary Issues in Women's Health

Featured

Publication Date:

August 2023

Pharmacogenetic interactions of efavirenz or rifampin and isoniazid with levonorgestrel emergency contraception during treatment of HIV or tuberculosis

Featured

Publication Date:

August 2023

Performance of spirometry assessment at TB diagnosis

Featured

Publication Date:

July 2023

Children deserve simple, short, safe, and effective treatment for rifampicin-resistant tuberculosis

Featured

Publication Date:

May 2023

Children deserve simple, short, safe, and effective treatment for rifampicin-resistant tuberculosis

Featured

Publication Date:

March 2023

Adverse Pregnancy Outcomes among HIV-infected Women Taking Isoniazid Preventive Therapy During the First Trimester

Featured

Publication Date:

February 2023

Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial

Featured

Publication Date:

February 2023

Long-Term Benefits from Early Antiretroviral Therapy Initiation in HIV Infection

Featured

Publication Date:

December 2022

A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis

Featured

Publication Date:

October 2022

Tuberculosis and Sexual and Reproductive Health of Women in Four African Countries

Featured

Publication Date:

October 2022

Tuberculosis and Sexual and Reproductive Health of Women in Four African Countries

Featured

Publication Date:

October 2022

Rifapentine with and without moxifloxacin for pulmonary tuberculosis in people with HIV

Featured

Publication Date:

September 2022

Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis

Featured

Publication Date:

September 2022

Post-COVID-19 condition 3 months after hospitalisation with SARS-CoV-2 in South Africa: a prospective cohort study

Featured

Publication Date:

July 2022

Impact of direct-acting antiviral treatment of hepatitis C on the quality of life of adults in Ukraine

Featured

Publication Date:

July 2022

Applying machine learning and predictive modeling to retention and viral suppression in South African HIV treatment cohorts

Featured

Publication Date:

May 2022

Proposed Linezolid Dosing Strategies to Minimize Adverse Events for Treatment of Extensively Drug-Resistant Tuberculosis

Featured

Publication Date:

May 2022

Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study

Featured

Publication Date:

May 2022

Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 InfectionC

Featured

Publication Date:

April 2022

Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study

Featured

Publication Date:

April 2022

Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study

Featured

Publication Date:

April 2022

infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial

Featured

Publication Date:

March 2022

Treatment of Rifampicin-Resistant Tuberculosis Disease and Infection in Children: Key Updates, Challenges and Opportunities

Featured

Publication Date:

February 2022

Hepatitis B surface antigen and hepatitis B RNA changes in HIV/hepatitis B virus co-infected participants receiving hepatitis B virus-active antiretroviral

Featured

Publication Date:

February 2022

Mitigation strategies to safely conduct HIV treatment research in the context of COVID-19

Featured

Publication Date:

February 2022

Guiding equitable prioritisation of COVID-19 vaccine distribution and strategic deployment in South Africa to enhance effectiveness and access to vulnerable communities and prevent waste

Featured

Publication Date:

February 2022

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

Featured

Publication Date:

February 2022

Lung and blood early biomarkers for host-directed tuberculosis therapies: Secondary outcome measures from a randomized controlled tria

Featured

Publication Date:

January 2022

Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis

Featured

Publication Date:

December 2021

Sterile tuberculous granuloma in a patient with XDR-TB treated with bedaquiline, pretomanid and linezolid

Featured

Publication Date:

November 2021

Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study

Featured

Publication Date:

October 2021

Effectiveness of GenoType MTBDRsl in excluding TB drug resistance in a clinical trial

Featured

Publication Date:

October 2021

Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB/XDR assay: a cross-sectional multicentre diagnostic accuracy study

Featured

Publication Date:

September 2021

Operational characteristics of 30 lateral flow immunoassays used to identify COVID-19 immune response

Featured

Publication Date:

September 2021

Resistance to Mycobacterium tuberculosis Infection Among Household Contacts: A Multinational Study

Featured

Publication Date:

August 2021

Thromboembolic Events in the South African Ad26.COV2.S Vaccine Study

Featured

Publication Date:

July 2021

Sexually transmitted infections among HIV serodiscordant partners: A secondary analysis of HIV Prevention Trial Network 052

Featured

Publication Date:

July 2021

QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial

Featured

Publication Date:

June 2021

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Featured

Publication Date:

May 2021

Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.

Featured

Publication Date:

May 2021

The Role of Remdesivir in South Africa: Preventing COVID-19 Deaths Through Increasing Intensive Care Unit Capacity

Featured

Publication Date:

April 2021

Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine

Featured

Publication Date:

March 2021

Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial

Featured

Publication Date:

February 2021

Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results

Featured

Publication Date:

January 2021

Human Papillomavirus Vaccination Prior to Loop Electroexcision Procedure Does Not Prevent Recurrent Cervical High-grade Squamous Intraepithelial Lesions in Women Living With Human Immunodeficiency Virus

Featured

Publication Date:

January 2021

Adaptation of WHO's generic tuberculosis patient cost instrument for a longitudinal study in Africa

Featured

Publication Date:

January 2021

Mapping the cervical cancer screening cascade among women living with HIV in Johannesburg, South Africa

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

CHRU’s scientific output and contribution

CHRU Publications

Building sustainable clinical trial sites in Sub-Saharan Africa through networking, infrastructure improvement, training and conducting clinical studies: The PanACEA approach

The lived experiences of Tuberculosis survivors during the COVID-19 pandemic and government lockdown in South Africa: a qualitative analysis

Contemporary Issues in Women's Health

Pharmacogenetic interactions of efavirenz or rifampin and isoniazid with levonorgestrel emergency contraception during treatment of HIV or tuberculosis

Performance of spirometry assessment at TB diagnosis

Children deserve simple, short, safe, and effective treatment for rifampicin-resistant tuberculosis

Children deserve simple, short, safe, and effective treatment for rifampicin-resistant tuberculosis

Adverse Pregnancy Outcomes among HIV-infected Women Taking Isoniazid Preventive Therapy During the First Trimester

Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial

Long-Term Benefits from Early Antiretroviral Therapy Initiation in HIV Infection

A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis

Tuberculosis and Sexual and Reproductive Health of Women in Four African Countries

Tuberculosis and Sexual and Reproductive Health of Women in Four African Countries

Rifapentine with and without moxifloxacin for pulmonary tuberculosis in people with HIV

Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis

Post-COVID-19 condition 3 months after hospitalisation with SARS-CoV-2 in South Africa: a prospective cohort study

Impact of direct-acting antiviral treatment of hepatitis C on the quality of life of adults in Ukraine

Applying machine learning and predictive modeling to retention and viral suppression in South African HIV treatment cohorts

Proposed Linezolid Dosing Strategies to Minimize Adverse Events for Treatment of Extensively Drug-Resistant Tuberculosis

Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study

Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 InfectionC

Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study

Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study

infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial

Treatment of Rifampicin-Resistant Tuberculosis Disease and Infection in Children: Key Updates, Challenges and Opportunities

Hepatitis B surface antigen and hepatitis B RNA changes in HIV/hepatitis B virus co-infected participants receiving hepatitis B virus-active antiretroviral

Mitigation strategies to safely conduct HIV treatment research in the context of COVID-19

Guiding equitable prioritisation of COVID-19 vaccine distribution and strategic deployment in South Africa to enhance effectiveness and access to vulnerable communities and prevent waste

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

Lung and blood early biomarkers for host-directed tuberculosis therapies: Secondary outcome measures from a randomized controlled tria

Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis

Sterile tuberculous granuloma in a patient with XDR-TB treated with bedaquiline, pretomanid and linezolid

Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study

Effectiveness of GenoType MTBDRsl in excluding TB drug resistance in a clinical trial

Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB/XDR assay: a cross-sectional multicentre diagnostic accuracy study

Operational characteristics of 30 lateral flow immunoassays used to identify COVID-19 immune response

Resistance to Mycobacterium tuberculosis Infection Among Household Contacts: A Multinational Study

Thromboembolic Events in the South African Ad26.COV2.S Vaccine Study

Sexually transmitted infections among HIV serodiscordant partners: A secondary analysis of HIV Prevention Trial Network 052

QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.

The Role of Remdesivir in South Africa: Preventing COVID-19 Deaths Through Increasing Intensive Care Unit Capacity

Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine

Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial

Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results

Human Papillomavirus Vaccination Prior to Loop Electroexcision Procedure Does Not Prevent Recurrent Cervical High-grade Squamous Intraepithelial Lesions in Women Living With Human Immunodeficiency Virus

Adaptation of WHO's generic tuberculosis patient cost instrument for a longitudinal study in Africa

Mapping the cervical cancer screening cascade among women living with HIV in Johannesburg, South Africa

Year

Designing an optimal HIV programme for South Africa: Does the optimal package change when diminishing returns are considered?

Prevalence of Anal Human Papillomavirus (HPV) and Performance of Cepheid Xpert and Hybrid Capture 2 (hc2) HPV Assays in South African HIV-Infected Women

Changing the South African National Antiretroviral therapy guidelines: The role of cost modelling

Prevalence of Anal HPV and Anal Dysplasia in HIV-Infected Women from Johannesburg, South Africa

A new cascade of HIV care for the era of “treat all”

Does disseminated nontuberculosis mycobacterial disease cause false-positive Determine B-LAM lateral flow assay results? A retrospective review

Cohort profile: Right to Care Clinical HIV Cohort, South Africa

Evidence for scaling up HIV treatment in sub-Saharan Africa: A call for incorporating health system constraints

Timing of pregnancy, postpartum risk of Virologic failure and loss to follow-up among HIV-positive women

Predicting the Need for Third-Line Antiretroviral Therapy by Identifying Patients at High Risk for Failing Second-Line Antiretroviral Therapy in South Africa

Lessons learnt from the introduction of the contraceptive implant in South Africa

Revealed willingness-to-pay versus standard cost-effectiveness thresholds: Evidence from the South African HIV Investment Case

Mobility and Clinic Switching Among Postpartum Women Considered Lost to HIV Care in South Africa

Turning the tide against tuberculosis

Immediate Initiation of Antiretroviral Therapy for HIV Infection Accelerates Bone Loss Relative to Deferring Therapy: Findings from the START Bone Mineral Density Substudy, a Randomized Trial

Characterizing breast conditions at an open-access breast clinic in South Africa: a model that is more than cancer care for a resource-limited setting

Excellent retention, virologic and clinical outcomes after transitioning from an antiretroviral treatment clinical trial to locally-provided care and treatment in Africa

Cryotherapy reduces progression of cervical intraepithelial neoplasia grade 1 in South African HIV-infected women: a randomized, controlled trial

Adverse drug reactions during drug-resistant TB treatment in high HIV prevalence settings: a systematic review and meta-analysis

Simplified clinical algorithm for identifying patients eligible for immediate initiation of antiretroviral therapy for HIV (SLATE): protocol for a randomized evaluation

Cervical cancer risk and impact of Pap-based screening in HIV-positive women on antiretroviral therapy in Johannesburg, South Africa

HIV viral load as an independent risk factor for tuberculosis in South Africa: collaborative analysis of cohort studies

Insulin-Like Growth Factor Is Associated with Changes in Body Composition with Antiretroviral Therapy Initiation

Virologic outcomes in early antiretroviral treatment: HPTN 052

A new cascade of HIV care for the era of “treat all”

The High Cost of HIV-Positive Inpatient Care at an Urban Hospital in Johannesburg, South Africa

Treatment initiation among persons diagnosed with drug-resistant tuberculosis in Johannesburg, South Africa

Combination of baseline plasma immune markers can predict therapeutic response in multidrug-resistant tuberculosis